Suppression of Antibody-mediated and Cell-mediated Murine Immunity by the Carcinogen N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide

Don B. Headley, Samuel Monroe Cohen, George T. Bryan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

N-[4-(5-Nitro-2-furyI)-2-thiazolyl]acetamide (NFTA) administered at 1000 ppm in diet to mice for 12 weeks induced a high incidence of lymphocytic leukemia. Effects of NFTA on antibody-mediated immunity and cell-mediated immunity of BALB/c mice were studied using the spleen plaque assay for detection of immunoglobulin M-producing cells and the graft-versus-host (GVH) reaction, respectively. NFTA suppressed both responses. With the spleen plaque assay, the number of antibody-forming cells (AFC) to sheep red blood cells was significantly less than in unmedicated, control mice after treated mice received NFTA at 1000 ppm for 6 days. The GVH reaction was not suppressed at 21 days, but was severely suppressed at 70 days, prior to the histological appearance of leukemia. Effect of dose was studied by administering NFTA at 100, 250, 500, and 1000 ppm of diet for 13 to 14 weeks and then determining the response in the spleen plaque assay and GVH reactions. The ratio of AFC/ spleen of NFTA-treated groups to AFC/spleen of an unmedicated control group, at the above specified doses, was 0.86, 0.22, 0.33, and 0.54 in ascending dosage order beginning with 100 ppm. For the GVH reaction, the suppression of the cell-mediated immunity was directly proportional to the dose of NFTA. Suppression of the antibody-mediated immunity in relation to the induction of leukemia at 28 weeks was studied by feeding NFTA at 500 ppm for 14 weeks, followed by unmedicated diet for 14 weeks. During the 11th week, mice were immunized with SRBC; 5 days later the spleens were removed and the spleen plaque assay was performed. Eight of 18 mice fed NFTA developed leukemia. The number of AFC/spleen was 78 x 103 ± 34 for those with leukemia and 68 x 103 ± 24 (p > 0.5) for those without leukemia, compared with 170 x 103 ± 74 for the control mice (p < 0.01 for both groups, compared with controls). A closely related carcinogenic nitrofuran, N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide did not suppress the antibody-mediated immunity response measured during the 11th week of administration.

Original languageEnglish (US)
Pages (from-to)974-979
Number of pages6
JournalCancer Research
Volume37
Issue number4
StatePublished - Jan 1 1976

Fingerprint

Cellular Immunity
Carcinogens
Spleen
Antibodies
Leukemia
Transplants
Diet
Immunity
Nitrofurans
Lymphoid Leukemia
furothiazole
acetamide
Antibody-Producing Cells
Immunoglobulin M
Sheep
Erythrocytes
Control Groups
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Suppression of Antibody-mediated and Cell-mediated Murine Immunity by the Carcinogen N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide. / Headley, Don B.; Cohen, Samuel Monroe; Bryan, George T.

In: Cancer Research, Vol. 37, No. 4, 01.01.1976, p. 974-979.

Research output: Contribution to journalArticle

@article{021eb4b1279c453892a0350cff4ad753,
title = "Suppression of Antibody-mediated and Cell-mediated Murine Immunity by the Carcinogen N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide",
abstract = "N-[4-(5-Nitro-2-furyI)-2-thiazolyl]acetamide (NFTA) administered at 1000 ppm in diet to mice for 12 weeks induced a high incidence of lymphocytic leukemia. Effects of NFTA on antibody-mediated immunity and cell-mediated immunity of BALB/c mice were studied using the spleen plaque assay for detection of immunoglobulin M-producing cells and the graft-versus-host (GVH) reaction, respectively. NFTA suppressed both responses. With the spleen plaque assay, the number of antibody-forming cells (AFC) to sheep red blood cells was significantly less than in unmedicated, control mice after treated mice received NFTA at 1000 ppm for 6 days. The GVH reaction was not suppressed at 21 days, but was severely suppressed at 70 days, prior to the histological appearance of leukemia. Effect of dose was studied by administering NFTA at 100, 250, 500, and 1000 ppm of diet for 13 to 14 weeks and then determining the response in the spleen plaque assay and GVH reactions. The ratio of AFC/ spleen of NFTA-treated groups to AFC/spleen of an unmedicated control group, at the above specified doses, was 0.86, 0.22, 0.33, and 0.54 in ascending dosage order beginning with 100 ppm. For the GVH reaction, the suppression of the cell-mediated immunity was directly proportional to the dose of NFTA. Suppression of the antibody-mediated immunity in relation to the induction of leukemia at 28 weeks was studied by feeding NFTA at 500 ppm for 14 weeks, followed by unmedicated diet for 14 weeks. During the 11th week, mice were immunized with SRBC; 5 days later the spleens were removed and the spleen plaque assay was performed. Eight of 18 mice fed NFTA developed leukemia. The number of AFC/spleen was 78 x 103 ± 34 for those with leukemia and 68 x 103 ± 24 (p > 0.5) for those without leukemia, compared with 170 x 103 ± 74 for the control mice (p < 0.01 for both groups, compared with controls). A closely related carcinogenic nitrofuran, N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide did not suppress the antibody-mediated immunity response measured during the 11th week of administration.",
author = "Headley, {Don B.} and Cohen, {Samuel Monroe} and Bryan, {George T.}",
year = "1976",
month = "1",
day = "1",
language = "English (US)",
volume = "37",
pages = "974--979",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Suppression of Antibody-mediated and Cell-mediated Murine Immunity by the Carcinogen N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide

AU - Headley, Don B.

AU - Cohen, Samuel Monroe

AU - Bryan, George T.

PY - 1976/1/1

Y1 - 1976/1/1

N2 - N-[4-(5-Nitro-2-furyI)-2-thiazolyl]acetamide (NFTA) administered at 1000 ppm in diet to mice for 12 weeks induced a high incidence of lymphocytic leukemia. Effects of NFTA on antibody-mediated immunity and cell-mediated immunity of BALB/c mice were studied using the spleen plaque assay for detection of immunoglobulin M-producing cells and the graft-versus-host (GVH) reaction, respectively. NFTA suppressed both responses. With the spleen plaque assay, the number of antibody-forming cells (AFC) to sheep red blood cells was significantly less than in unmedicated, control mice after treated mice received NFTA at 1000 ppm for 6 days. The GVH reaction was not suppressed at 21 days, but was severely suppressed at 70 days, prior to the histological appearance of leukemia. Effect of dose was studied by administering NFTA at 100, 250, 500, and 1000 ppm of diet for 13 to 14 weeks and then determining the response in the spleen plaque assay and GVH reactions. The ratio of AFC/ spleen of NFTA-treated groups to AFC/spleen of an unmedicated control group, at the above specified doses, was 0.86, 0.22, 0.33, and 0.54 in ascending dosage order beginning with 100 ppm. For the GVH reaction, the suppression of the cell-mediated immunity was directly proportional to the dose of NFTA. Suppression of the antibody-mediated immunity in relation to the induction of leukemia at 28 weeks was studied by feeding NFTA at 500 ppm for 14 weeks, followed by unmedicated diet for 14 weeks. During the 11th week, mice were immunized with SRBC; 5 days later the spleens were removed and the spleen plaque assay was performed. Eight of 18 mice fed NFTA developed leukemia. The number of AFC/spleen was 78 x 103 ± 34 for those with leukemia and 68 x 103 ± 24 (p > 0.5) for those without leukemia, compared with 170 x 103 ± 74 for the control mice (p < 0.01 for both groups, compared with controls). A closely related carcinogenic nitrofuran, N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide did not suppress the antibody-mediated immunity response measured during the 11th week of administration.

AB - N-[4-(5-Nitro-2-furyI)-2-thiazolyl]acetamide (NFTA) administered at 1000 ppm in diet to mice for 12 weeks induced a high incidence of lymphocytic leukemia. Effects of NFTA on antibody-mediated immunity and cell-mediated immunity of BALB/c mice were studied using the spleen plaque assay for detection of immunoglobulin M-producing cells and the graft-versus-host (GVH) reaction, respectively. NFTA suppressed both responses. With the spleen plaque assay, the number of antibody-forming cells (AFC) to sheep red blood cells was significantly less than in unmedicated, control mice after treated mice received NFTA at 1000 ppm for 6 days. The GVH reaction was not suppressed at 21 days, but was severely suppressed at 70 days, prior to the histological appearance of leukemia. Effect of dose was studied by administering NFTA at 100, 250, 500, and 1000 ppm of diet for 13 to 14 weeks and then determining the response in the spleen plaque assay and GVH reactions. The ratio of AFC/ spleen of NFTA-treated groups to AFC/spleen of an unmedicated control group, at the above specified doses, was 0.86, 0.22, 0.33, and 0.54 in ascending dosage order beginning with 100 ppm. For the GVH reaction, the suppression of the cell-mediated immunity was directly proportional to the dose of NFTA. Suppression of the antibody-mediated immunity in relation to the induction of leukemia at 28 weeks was studied by feeding NFTA at 500 ppm for 14 weeks, followed by unmedicated diet for 14 weeks. During the 11th week, mice were immunized with SRBC; 5 days later the spleens were removed and the spleen plaque assay was performed. Eight of 18 mice fed NFTA developed leukemia. The number of AFC/spleen was 78 x 103 ± 34 for those with leukemia and 68 x 103 ± 24 (p > 0.5) for those without leukemia, compared with 170 x 103 ± 74 for the control mice (p < 0.01 for both groups, compared with controls). A closely related carcinogenic nitrofuran, N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide did not suppress the antibody-mediated immunity response measured during the 11th week of administration.

UR - http://www.scopus.com/inward/record.url?scp=0017598094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017598094&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 974

EP - 979

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -